Partner Dov Grossman presented the panel “Brand-Generic Patent Litigation and Drug Regulation: An Ounce of Planning is Worth a Pound of Patent Protection” hosted by the Harvard-MIT Center for Regulatory Science. The program provided an overview of how patent litigation factors into the drug approval process, discussed the differing strategic considerations for brand and generic companies in such litigation, and reviewed various examples of “Hatch-Waxman” brand-generic patent litigation.